Skip to main content
ARGX
NASDAQ Life Sciences

argenx's $2.2B Forte Tender Offer Clears HSR Antitrust Review

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1,015.76
Mkt Cap
$62.992B
52W Low
$650.01
52W High
$1,009.745
52W Position info
56% above low
Off High info
at 52W high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ARGX sits 56% above its 52-week low of $650.01.

Summary

argenx's tender offer for Forte Biosciences cleared U.S. antitrust review, with the HSR waiting period expiring on August 18, 2026.


Key Events · M&A and Partnerships · ARGX

  • HSR Clearance Obtained

    The HSR waiting period expired at 11:59 p.m. ET on August 18, 2026, satisfying the HSR Clearance Condition for the tender offer.

  • Tender Offer Terms Unchanged

    The offer remains $77.00 per share in cash, net to seller, for all outstanding shares of Forte Biosciences.

  • Remaining Conditions

    The offer continues to be subject to other conditions set forth in the Offer to Purchase, including the tender of a majority of shares.

  • Timeline

    The tender offer was launched on August 6, 2026; this amendment confirms antitrust clearance as of August 18, 2026.


Analysis · ARGX · Life Sciences

The HSR waiting period expired on August 18, 2026, satisfying a key condition to argenx's $77.00 per share all-cash tender offer for Forte Biosciences. This removes a regulatory hurdle and moves the acquisition closer to completion, though the offer remains subject to other conditions.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARGX was trading at $1,015.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63B. The 52-week trading range was $650.01 to $1,009.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARGX - Latest Insights

ARGX
Nov 09, 2026, 8:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $945.64
Real-time Price: $947.49 info
Change: +$1.85 (+0.20%) info
Market Cap: $59.086B info
ARGX
Nov 09, 2026, 6:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $894.64
Real-time Price: $947.49 info
Change: +$52.85 (+6%) info
Market Cap: $59.086B info
ARGX
Oct 22, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $854.00
Real-time Price: $947.49 info
Change: +$93.49 (+11%) info
Market Cap: $59.086B info
ARGX
Oct 08, 2026, 6:51 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $795.20
Real-time Price: $947.49 info
Change: +$152.29 (+19%) info
Market Cap: $59.086B info
ARGX
Oct 08, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $791.00
Real-time Price: $947.49 info
Change: +$156.49 (+20%) info
Market Cap: $59.086B info